Small molecule glucagon release inhibitors with activity in human islets
PurposeType 1 diabetes (T1D) accounts for an estimated 5% of all diabetes in the United States, afflicting over 1.25 million individuals. Maintaining long-term blood glucose control is the major goal for individuals with T1D. In T1D, insulin-secreting pancreatic islet β-cells are destroyed by the im...
Main Authors: | Michael A. Kalwat, Karina Rodrigues-dos-Santos, Derk D. Binns, Shuguang Wei, Anwu Zhou, Matthew R. Evans, Bruce A. Posner, Michael G. Roth, Melanie H. Cobb |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1114799/full |
Similar Items
-
Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
by: Dorte B. Zilstorff, et al.
Published: (2024-03-01) -
Glucagon Shows Higher Sensitivity than Insulin to Grapeseed Proanthocyanidin Extract (GSPE) Treatment in Cafeteria-Fed Rats
by: Carme Grau-Bové, et al.
Published: (2021-03-01) -
Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist
by: Nicolas Damond, et al.
Published: (2016-04-01) -
New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions
by: Lucia La Sala, et al.
Published: (2021-09-01) -
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)